Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

RPR presents clinical findings with gpIIb/IIIa antagonist; product dropped due to dosing problems

Oct. 27, 1998

In vitro studies point to potent, long-lasting antiplatelet effects for XV-459/DMP-754

Oct. 26, 1998

Platelet collagen receptors targeted for development of new antiplatelet therapies

Oct. 23, 1998

Effects of DX-9065a on platelet activation reported at international congress

Oct. 23, 1998

SR-121787: the most potent fibrinogen antagonist reported to date

Oct. 23, 1998

New antiplatelet agents in the pipeline at Astra

Oct. 22, 1998

DuPont discloses heteroaromatic factor Xa inhibitors

Oct. 22, 1998

FDA Cardiovascular and Renal Drugs Advisory Committee meets this week

Oct. 20, 1998

Phase I study results reported for rNAPc2; further testing of novel anticoagulant recommended

Oct. 20, 1998

5-HT2A receptor antagonist shows potent antithrombotic activity in rat model

Oct. 19, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...